Loading...

ELAB PMGC HOLDINGS INC Product Launches 8-K Filing

PMGC

LB

PMGC HOLDINGS INC

(ELAB)

2025 8-K

Press Release Issued

License Agreement Update

Press Release Issued

Management Agreements Updated

Stock Split Announcement

New Investment Deal

Press Release Issued

Press Release Issued

License Agreement Signed

Acquisition Announcement

Equity Purchase Agreement

Investment Secured

Stock Split Announced

Press Release Issued

Annual Meeting Results

Press Release Issued

Asset Acquisition

Agreement Amendments

Equity Line Agreement

Share Capital Increase

Stock Split Announcement

Warrant Inducement Agreement

Executive Agreement Update

Management Changes

Asset Acquisitions

Asset Acquisitions

Investor Meetings

Investor Meetings

Management Changes

Equity Offerings

Letter of Intent

Consulting Agreement Amendm...

Consulting Agreement Amendm...

Securities Offering

Share Repurchase

License Termination

Stock Rights Update

FDA Meeting Request

Obesity Drug Presentation

Warrant Inducement

Warrant Agreement

Asset Disposition

Nasdaq Compliance

Management Changes

Asset Sale Agreement

Director Resignation

Reincorporation Update

Accountant Change

Bylaw Amendment

Nasdaq Compliance

Management Agreements

Drug Candidate Update

Nasdaq Compliance Issues

Nasdaq Delisting Notice

Investor Presentation

Clinical Study Results

External Links:

Northstrive Biosciences, a subsidiary of PMGC Holdings, presented its new obesity drug candidates EL-22 and EL-32 at the UCLA Obesity Symposium on February 7, 2025, sharing insights on their Myostatin-Engineered L. Casei Bacteria therapeutic approach.

AI Assistant

PMGC HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.